[CLSTR]
API
< Back to situations

[ORGANIZATION]

European Association for the Study of Diabetes

Featured in 47 tracked stories · first seen

Situations

[ACTIVE] [HEALTH] [US] [BR] [GB]

GLP-1 drugs: clinical trends, safety, and market shifts

323 clusters · 1175 sources · last updated

Latest: GLP-1 weight loss drugs may impact beer industry and pub culture

The clinical and economic landscape of GLP-1 medications continues to expand. Beyond obesity, research indicates potential benefits for psychiatric, respiratory, and neurodegenerative health. A retrospective study presen

[ACTIVE] [HEALTH] [US] [GB] [SE]

Expanding therapeutic uses and regulatory concerns for GLP-1

38 clusters · 164 sources · last updated

Latest: Semaglutide research explores broader benefits and drug metabolism effects

Medical research continues to expand the therapeutic potential of GLP-1 receptor agonists like semaglutide and tirzepatide. While semaglutide is widely used for weight loss and diabetes, new evidence suggests it may slow

[ACTIVE] [HEALTH] [CA] [GB] [US]

Type 2 diabetes remission and complication research

6 clusters · 24 sources · last updated

Latest: Diet and exercise program achieves 54% type 2 diabetes remission in young adults

Research into type 2 diabetes continues to focus on remission mechanisms and long-term complication risks. Remission is defined as maintaining an A1c level below 6.5% for at least three consecutive months without hypogly

[ACTIVE] [HEALTH] [DE] [US]

Type 2 diabetes management guideline updates

2 clusters · 2 sources · last updated

Latest: Diabetes treatment guidelines shift toward organ protection

The American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD) have issued new clinical consensus guidelines representing a shift in type 2 diabetes management. The updated approach

[ACTIVE] [HEALTH] [US] [AR] [CA]

Eli Lilly EloraTZP and retatrutide obesity drug clinicals

4 clusters · 38 sources · last updated

Latest: Eli Lilly's retatrutide outperforms Ozempic in weight loss trial

Eli Lilly has reported results from Phase 2b clinical trials for EloraTZP, a combination therapy involving eloralinantide and tirzepatide designed to treat obesity and type 2 diabetes. Data indicates the combination tar

[ACTIVE] [HEALTH] [US] [BA] [BR]

Health risks of ultra-processed food consumption

8 clusters · 35 sources · last updated

Latest: Research links ultra-processed foods and ADHD to increased mortality risks

Health experts and scientific research have highlighted the significant risks associated with the consumption of ultra-processed foods (UPFs). Cardiologist José Abellán warned that these foods contribute to a global obes

[QUIET] [HEALTH] [CA] [ES] [GB]

Diabetes research on environmental and lifestyle factors

2 clusters · 2 sources · last updated

Latest: New research links environmental factors and lifestyle to glucose levels

Recent scientific research has highlighted the impact of socioeconomic, environmental, and lifestyle factors on type 2 diabetes risk and management. Studies conducted in Canada and Europe have identified that residentia

[QUIET] [HEALTH] [US] [DE] [TW]

CBL-514 clinical trials for fat reduction

3 clusters · 27 sources · last updated

Latest: CBL-514 injection shows potential to destroy fat cells

Clinical trials for an experimental injection known as CBL-514, developed by Caliway Biopharmaceuticals, have demonstrated potential in reducing visceral and subcutaneous fat. The treatment functions by inducing apoptosi

[QUIET] [HEALTH] [DE] [IT] [US]

CBL-514 clinical trial results for obesity treatment

2 clusters · 6 sources · last updated

Latest: Caliway Biopharmaceuticals reports fat reduction with CBL-514

Clinical trials for CBL-514, an injectable drug developed by Caliway Biopharmaceuticals, have demonstrated potential in treating obesity by inducing apoptosis, or programmed cell death, in fat cells. Unlike traditional t

[QUIET] [HEALTH] [FR] [GB] [IT]

Red meat Neu5Gc and type 2 diabetes risk study

3 clusters · 21 sources · last updated

Latest: Dietary factors and Type 2 diabetes risk research

Preliminary results from a French observational study involving nearly 90,000 adults suggest a link between the consumption of red meat and an increased risk of type 2 diabetes. The research, presented at the European As

[QUIET] [HEALTH] [AU] [GB] [US]

AI voice analysis for type 2 diabetes screening

2 clusters · 7 sources · last updated

Latest: AI model detects type 2 diabetes through voice analysis

Researchers from Thymia and RMIT University have developed an artificial intelligence model designed to identify type 2 diabetes risk by analyzing subtle vocal changes, such as hoarseness, roughness, and breath control d

[QUIET] [HEALTH] [IT] [EU] [GB]

EASD diabetes congress in Milan

3 clusters · 49 sources · last updated

Latest: EASD 2026 in Milan showcases diabetes research and new medical technologies

The 62nd Congress of the European Association for the Study of Diabetes (EASD) in Milan highlighted significant advancements in diabetes management, screening, and therapeutic guidelines. Clinical discussions centered on

[QUIET] [HEALTH] [BR] [IT]

Advancements in obesity and diabetes medications

2 clusters · 6 sources · last updated

Latest: Obesity drugs show up to 30% weight loss at EASD 2026

Developments in obesity and diabetes treatments have focused on both regulatory approvals and clinical efficacy data. In Brazil, the National Health Surveillance Agency (Anvisa) approved generic registrations for liraglu

[QUIET] [HEALTH] [GB] [ME] [US]

Lifestyle impacts and management of type 2 diabetes

3 clusters · 35 sources · last updated

Latest: Dietary and exercise studies show progress in diabetes management

Research continues to demonstrate that lifestyle interventions can significantly mitigate the risk of developing type 2 diabetes. Previous studies involving the UK Biobank indicated that regular physical activity reduces

Also covered in